Epithelial retinal tears
Retinal epithelial tears may prove to be yet another indication for the use of intravitreal anti-VEGF agents, according to the results of a retrospective casecontrol study. The two-centre study involved nine patients with epithelial retinal tears who received no treatment and 12 patients who received treatment with a mean of 5.75 intravitreal injections of 0.3mg/0.09ml pegaptanib, 1.25mg/0.05ml bevacizumab, or 0.5mg/0.05ml ranibizumab, depending on the time of the intervention and centre where the patients received their therapy. From the third month to the final followup visit, the study’s investigators found a statistically significant difference between the mean visual acuities of the two groups (p = 0.034).
(Coco et al Ophthalmologica 2012; DOI: 10.1159/000338730)
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.